# SPECIALTY QUANTITY LIMIT PROGRAM

## **ICLUSIG** (ponatinib HCI)

### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

### **II. COVERED QUANTITIES**

Medication	Standard Limit	FDA-recommended dosing
Iclusig (ponatinib) 15 mg tablet	30 tablets per 30 days	Initial dosing: 45 mg orally once daily.  Initial dosing with strong CYP3A inhibitors or hepatic impairment (Child-Pugh A, B or C): 30 mg once daily.
Iclusig (ponatinib) 30 mg tablet	30 tablets per 30 days	
Iclusig (ponatinib) 45 mg tablet	30 tablets per 30 days	

#### **III. REFERENCES**

1. Iclusig [package insert]. Cambridge, MA: Ariad Pharmaceuticals, Inc.; October 2018.



pharmaceutical manufacturers that are not affiliated with CVS Caremark.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of